doi,PMID,section,ITC num,Ind studies num,questions,reviewer 1,reviewer 2,decision,identical,reviewer,Notes reviewer 1,Notes reviewer 2
10.1185/03007995.2011.576238,21524239,general_information,NA,NA,Medical Condition of Interest Name,chronic myeloid leukemia in the chronic phase,chronic myeloid leukemia,XXXX,FALSE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00471497,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00481247,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Treatment name 1,NA,NA,nilotinib,TRUE,BZ,unanchored despite the presence of a potential treatment arm to anchor to,"""As a negative control, the analysis was repeated for the randomized imatinib arms from ENESTnd and DASISION: if the trials were well-balanced after weighting, no average differences in comparably assessed outcomes would be expected between the imatinib arms. ""

""with individual patient values for all matched-on baseline characteristics included as predictors. "" predictors = ????"
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Treatment name 2,NA,NA,dasatinib,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),major molecular response,major molecular response by 12 months,major molecular response by 12 months,FALSE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,259,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,273,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,Number of covariates adjusted for/matched on,6,5,6,FALSE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",FALSE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,Primary outcome: unadjusted treatment effect,NA,9.40%,9.4,FALSE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,0.03,0.03,FALSE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,Primary outcome: adjusted treatment effect,10.9,10.80%,10.8,FALSE,BZ,NA,NA
10.1185/03007995.2011.576238,21524239,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.014,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,type 2 diabetes mellitus,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,general_information,NA,NA,Countries of last author affiliations,NA,NA,switzerland,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00368134,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,japan,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,2,Clinical Trial,Yes,No,XXXX,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00351832,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,japan,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,3,Clinical Trial,Yes,No,XXXX,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00411554,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,japan,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00127192,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,japan,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,japan,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NCT00371007,NA,NA,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Treatment name 1,vildagliptin,vildagliptin 50 mg twice daily,vildagliptin 50 mg twice daily,FALSE,BZ,"Anchored on voglibose
BMI (others)
Pooled results not reported, because it is just a meta-analysis on top of two MAICs
For the IPD sample size of this comparison, the size before application of inclusion and exclusion criteria are reported
","*Voglibose-controlled MAIC
*Covariates were taken from tables 2, but it's not mentioned in the text wether these are the covariates used in the MAIC
*BMI = other covariates"
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Treatment name 2,sitagliptin 50 mg,sitagliptin 50 mg once daily,sitagliptin 50 mg once daily,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,hba1c change from baseline to week 12,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,No,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Treatment name 1,vildagliptin,vildagliptin 50 mg twice daily,vildagliptin 50 mg twice daily,FALSE,BZ,Anchored on placebo,"*Placebo-controlled MAIC
*Covariates were taken from tables 2, but it's not mentioned in the text wether these are the covariates used in the MAIC
*BMI = other covariates"
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,2,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Treatment name 2,sitagliptin 50 mg,sitagliptin 50 mg once daily,sitagliptin 50 mg once daily,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,hba1c change from baseline to week 12,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,No,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Treatment name 1,vildagliptin,vildagliptin 50 mg twice daily,vildagliptin 50 mg twice daily,FALSE,BZ,Anchored on placebo,"*Placebo-controlled MAIC
*Covariates were taken from tables 2, but it's not mentioned in the text wether these are the covariates used in the MAIC
*BMI = other covariates"
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,2,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Treatment name 2,sitagliptin 100 mg,sitagliptin 100 mg once daily,sitagliptin 100 mg once daily,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Study 'number(s)' for treatment 2,4.5,4;5,4;5,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,hba1c change from baseline to week 12,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,No,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,163,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,156,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,-0.17,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.024,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,-0.2,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.009,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,188,NA,188,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",192,NA,192,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,72,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,73,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,76,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,72,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,-0.2,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.133,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,-0.56,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,145,175,145,FALSE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,149,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,76,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,72,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,-0.19,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.113,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,-0.35,TRUE,BZ,NA,NA
10.2165/11592490-000000000-00000,21819162,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.013,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,general_information,NA,NA,Medical Condition of Interest Name,advanced pancreatic neuroendocrine tumor,advanced pancreatic neuroendocrine tumors,XXXX,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,general_information,NA,NA,Countries of last author affiliations,NA,NA,canada,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00510068,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00428597,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Treatment name 1,NA,NA,everolimus,TRUE,BZ,"Sample sizes after exclusion for each arms not reported for radiant trial, so reporting the sample size before exclusion","""In the present study, a matching-adjusted indirect comparison was used to compare OS between everolimus and sunitinib arms. The placebo arm data were not used due to crossovers in both trials. Individual patients from the everolimus arm in RADIANT-3 were included, and were assigned the same weights previously used to match baseline medians and proportions to A6181111"""
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Treatment name 2,sunitinb,sunitinib,sunitinib,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Treatment name 1,everolimus,NA,everolimus,FALSE,BZ,"Sample sizes after exclusion for each arms not reported for everolimus versus placebo, so reporting the sample size before exclusion",NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Study 'number(s)' for treatment 1,1,NA,1,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Treatment name 2,placebo,NA,placebo,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Study 'number(s)' for treatment 2,2,NA,2,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Type of population-adjusted indirect comparisons performed,MAIC,NA,MAIC,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Anchored comparison?,No,NA,No,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Form of the indirect comparison,Simple (ie treatments effects extracted from two studies),NA,Simple (ie treatments effects extracted from two studies),FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall survival,NA,overall survival,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Primary outcome: variable type,Time-to-event,NA,Time-to-event,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Nothing mentioned, not reported",NA,"Nothing mentioned, not reported",FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,NA,No discussion (in the main text) of the status of prognostic factors of the variables,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,NA,No,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),No,NA,No,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Treatment name 1,NA,NA,everolimus,TRUE,BZ,"Sample sizes after exclusion for each arms not reported for everolimus versus placebo, so reporting the sample size before exclusion",Initial sample size IPD (Everolimus + Placebo) = 394
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Treatment name 2,NA,NA,sunitinib,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,86,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.69,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.087,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.81,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.383,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,207,207,207,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,85,NA,85,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,207,NA,207,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,NA,Not mentioned,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,NA,Yes,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,Number of covariates adjusted for/matched on,8,NA,8,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,Primary outcome: treatment effect contrast,HR,NA,HR,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,Primary outcome: unadjusted treatment effect,0.53,NA,0.53,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.002,NA,0.002,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,Primary outcome: adjusted treatment effect,0.61,NA,0.61,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.042,NA,0.042,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,86,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,85,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.9,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.695,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.84,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.578,TRUE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,207,207,207,FALSE,BZ,NA,NA
10.1186/2162-3619-2-32,24314093,results,3,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",203,203,203,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,severe hemophilia a,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01029340,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,2,Clinical Trial,Yes,No,XXXX,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01233258,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,2,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,3,Data source name (only if observational study or clinical trial without NCT),NA,NA,tarantino et al. (2004),TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,international,XXXX,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00243386,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,4,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,4,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00840086,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Treatment name 1,bay 81-8973 (recombinant factor viii),bay 81-8973,bay 81-8973 (recombinant factor viii),FALSE,BZ,NA,Weight = other covariate
10.2147/jbm.s104074,27445511,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Treatment name 2,NA,NA,rahf-pfm,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),annualized bleed rates for all bleeds (1-year),square root transformed abr : annualized bleed rates at 1 year (all bleed),square root transformed abr : annualized bleed rates at 1 year (all bleed),FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Treatment name 1,bay 81-8973 (recombinant factor viii),bay 81-8973,bay 81-8973 (recombinant factor viii),FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Treatment name 2,NA,NA,rahf-pfm,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),annualized bleed rates for all bleeds (1-year),annualized bleed rates at 1 year,annualized bleed rates for all bleeds (1-year),FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Treatment name 1,bay 81-8973 (recombinant factor viii),bay 81-8973,bay 81-8973 (recombinant factor viii),FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Treatment name 2,NA,NA,turoctocog alfa,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),annualized bleed rates for all bleeds (1-year),annualized bleed rates at 1 year,annualized bleed rates for all bleeds (1-year),FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,107,66,66,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,121,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,Number of covariates adjusted for/matched on,2,3,2,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Race/ethnicity","Age, Race/ethnicity, Other(s)","Age, Race/ethnicity",FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.1,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[-0.3;0.4],TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.1,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-0.3;0.4],TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,66,107,107,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,121,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,Number of covariates adjusted for/matched on,2,3,2,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Race/ethnicity","Age, Race/ethnicity, Other(s)","Age, Race/ethnicity",FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,-1.9,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.05,[-3.5;-0.4] p<0.05,[-3.5;-0.4] p<0.05,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,-1.5,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.18,[-3.7;-0.7],[-3.7;-0.7] p=0.18,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,150,107,150,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,121,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Race/ethnicity, Other(s)",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,-2.1,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.01,[-3.3;-1.0] p<0.05,[-3.3;-1.0] p<0.01,FALSE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,-2.2,TRUE,BZ,NA,NA
10.2147/jbm.s104074,27445511,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.05,[-3.4;-1.0] p<0.05,[-3.4;-1.0] p<0.05,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,general_information,NA,NA,Medical Condition of Interest Name,relapsingremitting multiple sclerosis,multiple sclerosis,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,general_information,NA,NA,Countries of first author affiliations,NA,NA,switzerland,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00420212,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00451451,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00004814,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),international,usa,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,4,Data source name (only if observational study or clinical trial without NCT),NA,NA,eur/can study,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,4,Phase of the clinical trial (clinical trial only),3,NA,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00099502,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Treatment name 1,dimethyl fumarate,delayed-release dimethyl fumarate,delayed-release dimethyl fumarate,FALSE,BZ,"Conduct an MAIC where a direct comparison exists
Conducted in the context of a meta-analysis
Doesn't report the results for the individual PAITC, only for the total meta analysis. Thus effect sizes are not reported in the form, despite results being reported in the meta analysis. 
Mixing open-label/placebo controlled and active controlled studies","Effectif non IPD (Intervention + Placebo) = 251
Effectif IPD (Intervention + Placebo) = 2651
ESS IPD (Intervention + Placebo) = 1032"
10.2217/cer-2016-0085,28350241,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Treatment name 2,NA,NA,glatiramer acetate,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Study 'number(s)' for treatment 2,3;4,3,3,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),annualized relapse rate,annualized relapse rate at 2 years,annualized relapse rate at 2 years,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),"Continuous (count, mean, ...)",FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Treatment name 1,dimethyl fumarate,delayed-release dimethyl fumarate,delayed-release dimethyl fumarate,FALSE,BZ,"N nonIPD 239
	N IPD 2651
	ESS 1206
	unadjusted RR pooled for GA US/EUR/CAN + direct comparison =  0.77   0.027
	adjusted RR pooled for GA US/EUR/CAN + direct comparison = 0.76  0.047
","Effectif non IPD (Intervention + Placebo) = 239
Effectif IPD (Intervention + Placebo) = 2651
ESS IPD (Intervention + Placebo) = 1206

Pas de rsultats donnes pour les MAIC 1 et 2 (formulaire 1 et 2) mais rsultat de la meta-analyse incluant la MAIC 1 et 2 :
Rate ratio before matching = 0.77   p=0.027
Rate ratio before matching = 0.76   p=0.047"
10.2217/cer-2016-0085,28350241,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Treatment name 2,NA,NA,glatiramer acetate,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Study 'number(s)' for treatment 2,3;4,4,4,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),annualized relapse rate,annualized relapse rate at 2 years,annualized relapse rate at 2 years,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Primary outcome: variable type,"Continuous (count, mean, ...)",Binary (eg rates),"Continuous (count, mean, ...)",FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Treatment name 1,dimethyl fumarate,delayed-release dimethyl fumarate,delayed-release dimethyl fumarate,FALSE,BZ,"Even if not anchored, sample sizes reported seem to be for both active and control comparators","Effectif non IPD (Intervention + Placebo) = 448
Effectif IPD (Intervention + Placebo) = 2651
ESS IPD (Intervention + Placebo) = 364"
10.2217/cer-2016-0085,28350241,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Treatment name 2,NA,NA,glatiramer acetate,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Anchored comparison?,No,Yes,No,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,12-week confirmed disability progression,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,1,NA,Primary outcome: treatment effect contrast,RR,Rate ratio,Rate ratio,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,1,NA,Primary outcome: unadjusted treatment effect,0.77,NA,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.027,NA,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,1,NA,Primary outcome: adjusted treatment effect,0.76,NA,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.047,NA,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,2,NA,Primary outcome: treatment effect contrast,RR,Rate ratio,Rate ratio,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,2,NA,Primary outcome: unadjusted treatment effect,0.77,NA,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",0.027,NA,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,2,NA,Primary outcome: adjusted treatment effect,0.76,NA,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.047,NA,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,RR,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.73,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.015,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.51,TRUE,BZ,NA,NA
10.2217/cer-2016-0085,28350241,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,general_information,NA,NA,Medical Condition of Interest Name,basal cell carcinoma,advanced basal cell carcinoma,XXXX,FALSE,BZ,NA,NA
10.1155/2017/6121760,28607774,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01327053,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,1,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00833417,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Treatment name 1,NA,NA,sonidegib,TRUE,BZ,"Doesn't report contrast effect, simply unadjusted and adjusted outcomes (+ CI)","""The indirect comparison is not anchored to a common comparator (because the available data are based on two single arms of noncomparative trials), and therefore relative effects (e.g., relative risks and hazard ratios) cannot be examined."""
10.1155/2017/6121760,28607774,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Treatment name 2,NA,NA,vismodegib,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),overall response rate,objective response rate,objective response rate,FALSE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Primary outcome: variable type,Time-to-event,Binary (eg rates),Binary (eg rates),FALSE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,FALSE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,63,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,66,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,Past treatments for the disease of interest,TRUE,BZ,NA,NA
10.1155/2017/6121760,28607774,results,1,NA,Primary outcome: treatment effect contrast,NA,"Relative effects (e.g., relative risks and hazard ratios) has not been examined.",XXXX,FALSE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,general_information,NA,NA,Medical Condition of Interest Name,relapsed/refractory multiple myeloma,multiple myeloma,XXXX,FALSE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,general_information,NA,NA,Countries of first author affiliations,NA,NA,belgium,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,general_information,NA,NA,Countries of last author affiliations,NA,NA,spain,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00574288,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01985126,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,2,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01311687,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01712789,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Treatment name 1,nct01712789,daratumumab,daratumumab,FALSE,BZ,NCT01985126 is single arm because actually only difference in treatment regimens between arms,"Base case analysis

Creatinine clearance = Comorbidity

""Although a wide range of prognostic factors were accounted for in the matching process,"""
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Treatment name 2,pomalidomide + low-dose dexamethasone,pomalidomide + low?dose dexamethasone,pomalidomide + low-dose dexamethasone,FALSE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Treatment name 1,NA,NA,daratumumab,TRUE,BZ,NA,"Base case analysis

Creatinine clearance = Comorbidity

""Although a wide range of prognostic factors were accounted for in the matching process,""
"
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Treatment name 2,pomalidomide + low-dose dexamethasone,pomalidomide + low?dose dexamethasone,pomalidomide + low-dose dexamethasone,FALSE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,302,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,136,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,55,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,10,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.61,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.0005,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.56,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.0001,0.0041,0.0041,FALSE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,682,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,148,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,95,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,Number of covariates adjusted for/matched on,10,7,7,FALSE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.55,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.0001,<0 .0001,<0.0001,FALSE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.51,TRUE,BZ,NA,NA
10.1634/theoncologist.2017-0103,29192016,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.0001,<0 .0001,<0.0001,FALSE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,general_information,NA,NA,Medical Condition of Interest Name,symptomatic lumbar disc degeneration,lumbar total disc replacement,XXXX,FALSE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,general_information,NA,NA,Countries of last author affiliations,NA,NA,canada,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",Yes,No such section presenting competing interest/conflict of interest,XXXX,FALSE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00589797,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00295009,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Treatment name 1,total disc replacemen,total disc replacement (tdr),total disc replacement,FALSE,BZ,Non IPD trial in the USA according to princeps article,"""An anchored MAIC has advantages over unanchored MAIC, namely it only requires consideration and adjustment for relevant treatment effect modifiers. In contrast, an unanchored MAIC requires consideration and adjustment for both treatment effect modifiers and prognostic factors, which is inherently more difficult"" ==> from Supplementary Materials"
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Treatment name 2,NA,NA,fusion,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),incidence of progression in radiographic adjacent-level degeneration,5-year change in adjacent-level degeneration,5-year change in radiographic adjacent-level degeneration,FALSE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,43,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,175,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,139,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Age, Sex, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)",FALSE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,Primary outcome: unadjusted treatment effect,NA,0.28,0.28,FALSE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,[0.12;0.63],[0.12;0.63],FALSE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,Primary outcome: adjusted treatment effect,0.35,0.32,0.32,FALSE,BZ,NA,NA
10.1097/brs.0000000000002647,29570121,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.13;0.76],TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,relapsed and refractory classical hodgkins lymphoma,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,general_information,NA,NA,Countries of first author affiliations,NA,NA,canada,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02453594,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),unknown,NA,XXXX,FALSE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,study_information,NA,2,Clinical Trial,NA,NA,No,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,study_information,NA,2,Data source name (only if observational study or clinical trial without NCT),NA,NA,"cheah et al., 2016",TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Treatment name 1,NA,NA,pembrolizumab,TRUE,BZ,"Compares active treatment from single arm trial to observational study: very favorable context for the active treatment regarless of actual effect. **Seems like they do an STC, but basically center the covariates from the IPD trial to the value from the nonIPD trial by subtracting the mean of the nonIPD, and computes a linear regression using these new covariates values: to check that it comes down to the same thing as STC.**
covariates: prognostic factors, known, but didn't conduct a specific systematic review for that, but still checked ""clinical expert"" because it is the closest, more relevant than nothing reported
",Primary analysis of all BV failures from KEYNOTE-087
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Treatment name 2,NA,NA,st + ard of care,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Type of population-adjusted indirect comparisons performed,STC,MAIC,STC,FALSE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,Yes,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,FALSE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported",A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,Yes,FALSE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,83,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,175,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,Not mentioned,Not mentioned,FALSE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",FALSE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Denominator if ratio, or rightside if difference",TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,5,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[3.56;7.01],TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,6.35,TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[4.04;9.98],TRUE,BZ,NA,NA
10.1080/17474086.2018.1475226,29764245,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",175,NA,175,FALSE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,metastatic renal cell carcinoma,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,general_information,NA,NA,Countries of first author affiliations,NA,NA,canada,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,general_information,NA,NA,Countries of last author affiliations,NA,NA,uk,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00678392,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01865747,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Treatment name 1,NA,NA,axitinib,TRUE,BZ,Different results presented by other articles on similar drugs,"Axitinib (AXIS) : sample size before matching = 194

""Race was not included in the matching process as it was strongly correlated with geographic region."""
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Treatment name 2,NA,NA,cabozantinib,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,Yes,FALSE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,progression-free survival,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,Yes,Yes,FALSE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Treatment name 1,NA,NA,axitinib,TRUE,BZ,NA,"Axitinib (AXIS) : sample size before matching = 194

""Race was not included in the matching process as it was strongly correlated with geographic region."""
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Treatment name 2,NA,NA,everolimus,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",Yes,Yes,FALSE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,Yes,Yes,FALSE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,135,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,104,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,9,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)",FALSE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,1.15,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.423,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,194,NA,194,FALSE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,132,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,61,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,9,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)",FALSE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.53,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.002,TRUE,BZ,NA,NA
10.1186/s12885-018-5157-0,30567533,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,194,NA,194,FALSE,BZ,NA,NA
10.2147/ceor.s203482,31564931,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,acute myeloid leukemia,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,general_information,NA,NA,Countries of last author affiliations,usa,uk,XXXX,FALSE,BZ,NA,NA
10.2147/ceor.s203482,31564931,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01546038,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01074047,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00260832,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Treatment name 1,glasdegib,glasdegib + low-dose cytarabine.,glasdegib + low-dose cytarabine,FALSE,BZ,Extensive description of the covariates choice process. Results are reported for the full models. Say they use STC because of the sample size reduction caused by MAICs.,"Results are for the stepwise exponential approach ""as the chosen optimal model from following DSU guidance (Table 3), the stepwise exponential approach....""

HR (CI95) for full exponential STC : 0.446  [0.231;0.860]
"
10.2147/ceor.s203482,31564931,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Treatment name 2,NA,NA,azacitidine,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Treatment name 1,glasdegib,glasdegib + low-dose cytarabine.,glasdegib + low-dose cytarabine,FALSE,BZ,NA,"""Results are for the stepwise exponential approach """"as the chosen optimal model from following DSU guidance (Table 3), the stepwise exponential approach....""""

HR (CI95) for full exponential STC : 0.490  [0.259;0.924]
"""
10.2147/ceor.s203482,31564931,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Treatment name 2,NA,NA,decitabine,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Study 'number(s)' for treatment 2,2,3,3,FALSE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,STC,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,241,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,158,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,78,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,78,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,38,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,38,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,Number of covariates adjusted for/matched on,7,3,3,FALSE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",FALSE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.514,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.310;0.852],TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.424,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.228;0.789],TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,242,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,215,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,78,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,78,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,38,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,38,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,Number of covariates adjusted for/matched on,7,5,5,FALSE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)",FALSE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.565,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.351;0.909],TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.505,TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.269;0.949],TRUE,BZ,NA,NA
10.2147/ceor.s203482,31564931,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,Not mentioned,XXXX,FALSE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,general_information,NA,NA,Medical Condition of Interest Name,multiple myeloma,ansplant-ineligible newly diagnosed multiple myeloma,XXXX,FALSE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,general_information,NA,NA,Countries of first author affiliations,NA,NA,greece,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,Yes,No,NA,FALSE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02195479,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00689936,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Treatment name 1,daratumumabbortezomibmelphalanprednisone,d-vmp (daratumumabbortezomibmelphalanprednisone),daratumumabbortezomibmelphalanprednisone,FALSE,BZ,NA,"Rd continuous: lenalidomide and dexamethasone given in 28-day
cycles until disease progressioN

Renal function = Comorbitity"
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Treatment name 2,lenalidomidedexamethasone continuou,lenalidomidedexamethasone,lenalidomidedexamethasone continuous,FALSE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Treatment name 1,daratumumabbortezomibmelphalanprednisone,d-vmp (daratumumabbortezomibmelphalanprednisone),daratumumabbortezomibmelphalanprednisone,FALSE,BZ,NA,"Rd 18: lenalidomide and dexamethasone given for 18 cycles

Renal function = Comorbitity"
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Treatment name 2,lenalidomidedexamethasone 18 months (rd18),lenalidomidedexamethasone,lenalidomidedexamethasone 18 months (rd18),FALSE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Treatment name 1,daratumumabbortezomibmelphalanprednisone,d-vmp (daratumumabbortezomibmelphalanprednisone),daratumumabbortezomibmelphalanprednisone,FALSE,BZ,NA,"MPT: melphalan/prednisone/thalidomide

Renal function = Comorbitity"
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Treatment name 2,melphalanprednisonethalidomide,melphalanprednisonethalidomide (mpt),melphalanprednisonethalidomide,FALSE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,535,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,350,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,248,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.88,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.51,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.68,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.086,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,541,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,350,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,246,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.78,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.16,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.6,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.02,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,547,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,535,350,350,FALSE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,248,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,0.68,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.024,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.53,TRUE,BZ,NA,NA
10.1080/10428194.2019.1682571,31686559,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.003,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,general_information,NA,NA,Medical Condition of Interest Name,severe asthma,asthma,XXXX,FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,general_information,NA,NA,Countries of first author affiliations,NA,NA,france,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02075255,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01691508,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02528214,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Treatment name 1,NA,NA,benralizumab,TRUE,BZ,"No sample sizes for individual arms. Sample sizes for intervention and control arms: 
N IPD = 148
ESS = 72
N non IPD = 135",BMI = Comorbidit
10.1111/cea.13561,31943429,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Treatment name 2,NA,NA,mepolizumab,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean percentage of oral corticosteroids reduction,ocs (oral corticosteroids) dosage reduction from baseline to week 24,ocs (oral corticosteroids) dosage reduction from baseline to week 24,FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,Yes,No,No,FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Treatment name 1,NA,NA,benralizumab,TRUE,BZ,"N IPD = 142 
ESS = 36
N non IPD = 210","BMI = Comorbidit

Effectif tude 1 (Bras compar + bras placebo) = 148
ESS tude 1 (Bras compar + bras placebo) = 36
Effectif tude 3 (Bras compar + bras placebo) = 210"
10.1111/cea.13561,31943429,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Treatment name 2,NA,NA,dupilumab,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Study 'number(s)' for treatment 2,2,3,3,FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean percentage of oral corticosteroids reduction,ocs (oral corticosteroids) dosage reduction from baseline to week 24,ocs (oral corticosteroids) dosage reduction from baseline to week 24,FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,Yes,No,No,FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,20.1,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.1584,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,6.08,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",0.67,0.6737,0.67,FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1111/cea.13561,31943429,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,8.1,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.46,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,-0.71,TRUE,BZ,NA,NA
10.1111/cea.13561,31943429,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.94,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,general_information,NA,NA,Medical Condition of Interest Name,moderate-to-severe psoriasis,plaque psoriasis:,XXXX,FALSE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NCT01866163,NCT01928394,NCT01866163,FALSE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02132936,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,france,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,3,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01536886,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02462070,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02462122,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Treatment name 1,NA,NA,calcipotriene 0.005%/betamethasone dipropionate 0.064% foam,TRUE,BZ,Includes a medico economical analysis ; ESS total 2 arms = 586 (from 848 IPD),Individual patient data (IPD) were re-weighted to match the average baseline characteristics of those from the HP/TAZ lotion clinical studies using the Newton-Raphson algorithm (NLPNRA subroutine within the PROC IML).
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Treatment name 2,halobetasol 0.01%/tazarotene 0.045%,halobetasol 0.01%/tazarotene 0.045% lotion,halobetasol 0.01%/tazarotene 0.045%,FALSE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,4;5,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),physician's global assessment treatment success,"proportion of patients who achieved clear or almost clear skin (score of 0 or 1), with at least a 2-grade improvement in disease severity, as assessed by a 5-point pga (or iga) scale",physician's global assessment treatment success,FALSE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,249,276,276,FALSE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,142,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,649,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,199,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Rate difference,TRUE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,"Numerator if ratio, or left side if difference",NA,"Numerator if ratio, or left side if difference",FALSE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,Primary outcome: adjusted treatment effect,20.7,20.70%,20.7,FALSE,BZ,NA,NA
10.1080/13696998.2020.1722139,31985301,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,rheumatoid arthritis,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,general_information,NA,NA,Countries of first author affiliations,NA,NA,france,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",Not mentioned,Yes,XXXX,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01711359,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00109408,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01007435,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01039688,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00195663,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Treatment name 1,NA,NA,baricitinib,TRUE,BZ,NA,Matching by treatment arm
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Treatment name 2,NA,NA,adalimumab,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change in visual analogue scale for pain,change in pain (vas scale) from baseline to 6 months,change in pain (vas scale) from baseline to 6 months,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Treatment name 1,NA,NA,baricitinib,TRUE,BZ,ESS = 331,"Matching by treatment arm

Pas d'ESS pour methotrexate et Tocilizumab pour l'essai FUNCTION : ESS MTX+Tocilizumab = 333.1

Pas de comparaison de Baricitinib vs Tocilizumab (essai AMBITION) dans l'analyse principale"
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Treatment name 2,NA,NA,tocilizumab,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change in visual analogue scale for pain,change in pain (vas scale) from baseline to 6 months,change in pain (vas scale) from baseline to 6 months,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Treatment name 1,NA,NA,baricitinib,TRUE,BZ,NA,Matching by treatment arm
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Treatment name 2,NA,NA,tofacitinib,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change in visual analogue scale for pain,change in pain (vas scale) from baseline to 6 months,change in pain (vas scale) from baseline to 6 months,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Nothing mentioned, not reported","Nothing mentioned, not reported",FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,274,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,257,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,159,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,151.5,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,210,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,181.4,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,Number of covariates adjusted for/matched on,7,5,5,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,-12.1,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,<0.001,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,-12.3,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.001,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,159,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,210,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,Number of covariates adjusted for/matched on,7,5,5,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,Primary outcome: unadjusted treatment effect,NA,NA,-8.7,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.05,<=0.05,<=0.05,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,Primary outcome: adjusted treatment effect,-12.1,-7.3,-7.3,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",<0.05,<=0.05,<=0.05,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,292,292,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,287,287,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,373,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,186,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,159,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,146.5,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,210,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,177.8,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,Number of covariates adjusted for/matched on,7,5,5,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)",FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,Primary outcome: unadjusted treatment effect,NA,NA,-7.1,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",<0.05,<=0.05,<=0.05,FALSE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,-5.4,TRUE,BZ,NA,NA
10.1136/rmdopen-2019-001131,32371431,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",>0.05,NA,>0.05,FALSE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,general_information,NA,NA,Medical Condition of Interest Name,non-small cell lung cancer treatments,ros1 fusion-positive non-small cell lung cancer,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,general_information,NA,NA,Countries of first author affiliations,NA,NA,switzerland,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,general_information,NA,NA,Countries of last author affiliations,NA,NA,switzerland,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,1,EudraCT (only for clinical trials registered on clinicaltrialsregister.eu,NA,NA,2012-000148-88,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,italy,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02097810,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,3,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02568267,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00585195,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,5,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,5,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,5,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01828099,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,5,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,5,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,5,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,6,Patient-level data used,No,Yes,XXXX,FALSE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,6,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,6,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT00932893,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,6,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,6,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,study_information,NA,6,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Treatment name 1,NA,NA,entrectinib,TRUE,BZ,ALKA372-001   2012-000148-88  --> no information on clinicaltrialsregister.eu but information found there https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380583/,Smoking history = other covariates
10.2217/cer-2020-0063,32648475,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Treatment name 2,NA,NA,crizotinib,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Treatment name 1,NA,NA,entrectinib,TRUE,BZ,NA,Smoking history = other covariates
10.2217/cer-2020-0063,32648475,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Treatment name 2,pemetrexed + platinum followed by pemetrexed maintenance,pemetrexed + platinum + pemetrexed maintenance,pemetrexed + platinum followed by pemetrexed maintenance,FALSE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,5,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Treatment name 1,NA,NA,entrectinib,TRUE,BZ,NA,Smoking history = other covariates
10.2217/cer-2020-0063,32648475,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Treatment name 2,pemetrexed/docetaxel,chemotherapy,pemetrexed/docetaxel,FALSE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,6,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,53,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,53,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,34.18,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.471,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.112;1.034],TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,187,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,53,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,47.5,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.478,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.167;0.918],TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,174,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,53,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",47.5,36.09,36.09,FALSE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.434,TRUE,BZ,NA,NA
10.2217/cer-2020-0063,32648475,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.157;0.755],TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,general_information,NA,NA,Medical Condition of Interest Name,hereditary transthyretin-mediated amyloidoisis with polyneuropathy,hereditary transthyretin-mediated amyloidosis with polyneuropathy,XXXX,FALSE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NCT03997383,NCT01960348,NCT01960348,FALSE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01737398,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,2,Phase of the clinical trial (clinical trial only),"2, 3",3,XXXX,FALSE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Treatment name 1,NA,NA,patisiran,TRUE,BZ,"Say in supplemental that they studied the weights, although the excerpt were they mention it seems to be a generic MAIC methodology description.  Extensive explanations provided in the supplemental materials, however, doesn't mention the notion of treatment effect modifiers.","BMI = others
covariates = from Table 1"
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Treatment name 2,NA,NA,inotersen,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean difference 15-month change in neuropathy mnis+7ionis score,15-month changes from baseline in mnis+7ionis (modified neuropathy impairment score +7),15-month changes from baseline in mnis+7ionis (modified neuropathy impairment score +7),FALSE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,112,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,60,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,148,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,90,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,77,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,47,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,Yes,No,Yes,FALSE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,9,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Means difference,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,-16.2,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.001,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,-12.3,TRUE,BZ,NA,NA
10.1080/14656566.2020.1811850,32892660,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.007,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,advanced hepatocellular carcinoma,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01658878,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,"1, 2",TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01908426,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Treatment name 1,NA,NA,nivolumab + ipilimumab,TRUE,BZ,MAIC in the context of a NMA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Treatment name 2,NA,NA,placebo,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),NA,NA,overall survival,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset",TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,237,137,237,FALSE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,50,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.35,TRUE,BZ,NA,NA
10.2217/cer-2020-0236,33442996,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.21;0.58],TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,nonmetastatic castration-resistant prostate cancer,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",Yes,No such section presenting competing interest/conflict of interest,XXXX,FALSE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02200614,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01946204,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02003924,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Treatment name 1,NA,NA,darolutamide,TRUE,BZ,"
Similar opposite MAIC conducted for ITC 1, inverting IPD and non IPD reported no statistical differences, although reported outcomes were slightly different, and matching set were different too, illustrating very well the publication bias here. 
",NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Treatment name 2,NA,NA,apalutamide,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),fall risk,risk of prespecified aes : risk of fall,Risk of fall,FALSE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),FALSE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Treatment name 1,NA,NA,darolutamide,TRUE,BZ,NA,Region = other
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Treatment name 2,NA,NA,enzalutamide,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Study 'number(s)' for treatment 2,2,3,3,FALSE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),fall risk,risk of prespecified aes(advers effects) : risk of fall,Risk of fall,FALSE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,806,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,401,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,943,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,604,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,553,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,391,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,7,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",FALSE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,Primary outcome: adjusted treatment effect,-6.3,-6.30%,-6.3,FALSE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.043,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,933,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,468,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,943,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,580,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,553,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,395,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,8,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)","Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)",FALSE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Risk difference,TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,Primary outcome: adjusted treatment effect,-6.3,-6.30%,-6.3,FALSE,BZ,NA,NA
10.1097/ju.0000000000001767,33818140,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.004,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,nonmetastatic castration-resistant prostate cancer,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,Academic,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,general_information,NA,NA,Mentioned sources of funding,"Public grants, Pharmaceutical Industry",Pharmaceutical Research and Manufacturers of America Foundation 2020 Predoctoral Fellowship in Health Outcomes Research and the Ellen B. Gold Scholarship,XXXX,FALSE,BZ,NA,NA
10.1093/jnci/djab071,33830214,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01314118,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,usa,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01946204,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Treatment name 1,NA,NA,abiraterone acetate,TRUE,BZ,"MAIC associated with a network meta-analysis, thus may explain why they gave less details about their methodology","Population de  IMAAGEN ajuste sur celle de SPARTAN (N = 1207) ou du bras placebo de SPARTAN (N = 401)  ?
Spartant (1207) = Apalutamide (605) + Placebo (401)"
10.1093/jnci/djab071,33830214,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Treatment name 2,NA,NA,placebo,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),metastasis free survival,metastasis-free survival (mfs),metastasis-free survival,FALSE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",No,Yes,No,FALSE,BZ,NA,NA
10.1093/jnci/djab071,33830214,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,806,1207,1207,FALSE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,131,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,81,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials",TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest",TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.22,TRUE,BZ,NA,NA
10.1093/jnci/djab071,33830214,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",[0.12;0.41],[0.12;0.42],[0.12;0.41],FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,chronic lymphocytic leukemia,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,general_information,NA,NA,Countries of last author affiliations,NA,NA,uk,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02475681,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01722487,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02264574,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02242942,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Treatment name 1,acalabrutinib,acalabrutinib + obinutuzumab,acalabrutinib + obinutuzumab,FALSE,BZ,"Show safety outcomes in the abstract first, maybe because there are statistical significant differences between treatment arms, whereas there are none in the efficacy outcomes. But doesn't show safety outcome first ni the body 
The fact that the included variables are prognostic factors is somewhat implied, but doesn't say it explicitely",Creatinine clearance = comorbidity
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Treatment name 2,NA,NA,ibrutinib,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Treatment name 1,NA,NA,acalabrutinib,TRUE,BZ,NA,Creatinine clearance = comorbidity
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Treatment name 2,NA,NA,ibrutinib,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Treatment name 1,NA,NA,acalabrutinib + obinutuzumab,TRUE,BZ,NA,Creatinine clearance = comorbidity
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Treatment name 2,NA,NA,ibrutinib + obinutuzumab,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,3,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Treatment name 1,NA,NA,acalabrutinib,TRUE,BZ,NA,Creatinine clearance = comorbidity
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Treatment name 2,obinutuzumab,ibrutinib + obinutuzumab,ibrutinib + obinutuzumab,FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,4,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Treatment name 1,NA,NA,acalabrutinib + obinutuzumab,TRUE,BZ,NA,Creatinine clearance = other
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Treatment name 2,NA,NA,venetoclax + obinutuzumab,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,5,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Treatment name 1,NA,NA,acalabrutinib,TRUE,BZ,NA,Creatinine clearance = comorbidity
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Treatment name 2,NA,NA,venetoclax + obinutuzumab,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),progression free survival,progression-free survival,progression-free survival,FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Primary outcome: variable type,NA,NA,Time-to-event,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Justification for selecting variables to be included in the adjustment model (in the main text),A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),"Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)","Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,methodology,6,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,136,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,126,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,59,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,12,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,0.61,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.3,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,136,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,136,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,79,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,12,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,0.92,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.83,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,Sample size of the population of interest in the non IPD treatment arm,97,113,113,FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,113,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,97,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,Number of covariates adjusted for/matched on,NA,NA,12,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,Primary outcome: adjusted treatment effect,NA,NA,0.55,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,3,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.11,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,113,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,114,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,97,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,Number of covariates adjusted for/matched on,NA,NA,12,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,Primary outcome: adjusted treatment effect,NA,NA,0.53,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,4,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.08,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,216,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,83,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,43,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,Number of covariates adjusted for/matched on,NA,NA,12,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,Primary outcome: adjusted treatment effect,NA,NA,0.78,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,5,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.57,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,216,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,96,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,51,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,Number of covariates adjusted for/matched on,NA,NA,12,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,Primary outcome: treatment effect contrast,NA,NA,HR,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,Primary outcome: adjusted treatment effect,NA,NA,1.24,TRUE,BZ,NA,NA
10.1080/10428194.2021.1913144,33955326,results,6,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.59,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,hemophilia b,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,general_information,NA,NA,Countries of first author affiliations,NA,NA,sweden,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,general_information,NA,NA,Countries of last author affiliations,NA,NA,germany,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01027364,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,1,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01496274,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,"2, 3",TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,study_information,NA,2,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Treatment name 1,prior prophylaxis rfixfc,rfixfc (regimen prior to study entry : prior prophylaxis),prior prophylaxis rfixfc,FALSE,BZ,"Concludes for equivalence when the hypothesis was for superiority
Matches on SD for age and body weights and number of bleeding events
Never mention the notion of treatment effect modifiers/prognostic factors 
Mention of the target population 
",Treatment regimen prior to study entry : prior prophylaxis
10.2147/jbm.s312885,34285621,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Treatment name 2,prior prophylaxis rix-fp,rix-fp,prior prophylaxis rix-fp,FALSE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),annualized bleeding rate,annualized bleeding rate (abr),annualized bleeding rate (abr),FALSE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,No,FALSE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Treatment name 1,prior episodic treatment rfixfc,rfixfc (treatment regimen prior to study entry : prior on-dem +  treatment),prior episodic treatment rfixfc,FALSE,BZ,NA,Treatment regimen prior to study entry : prior on-demand treatment
10.2147/jbm.s312885,34285621,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Treatment name 2,prior episodic treatment rix-fp,rix-fp,prior episodic treatment rix-fp,FALSE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),annualized bleeding rate,annualized bleeding rate (abr),annualized bleeding rate (abr),FALSE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",Yes,No,Yes,FALSE,BZ,NA,NA
10.2147/jbm.s312885,34285621,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,40,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,45,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,26,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)",TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Incidence Rate Ratio,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,1.18,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.67;2.10],TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,19,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,42,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,10,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,4,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)",TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,Primary outcome: treatment effect contrast,NA,NA,Incidence Rate Ratio,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,1.01,TRUE,BZ,NA,NA
10.2147/jbm.s312885,34285621,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.40;2.57],TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,paroxysmal nocturnal hemoglobinuria,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03500549,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03056040,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Treatment name 1,NA,NA,pegcetacoplan,TRUE,BZ,"Adjust for different characteristics depending on endpoints types
Detailed description of the status of baseline characteristics (treatment effect modifiers/prognositc factors)
However, huge differences in anchor arm treatment effect!!
*Incorrect use of outcomes scales when comparing outcomes: mean differences*
No ESS no unadjusted results reported",NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Treatment name 2,NA,NA,ravulizumab,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),transfusion avoidance,proportion of patients with transfusion avoidance,proportion of patients with transfusion avoidance,FALSE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion),TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,97,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,98,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,36,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,32,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,5,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity",TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,Primary outcome: treatment effect contrast,Rate difference,Proportions difference,Proportions difference,FALSE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,Primary outcome: adjusted treatment effect,0.714,71.39%,0.714,FALSE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,<0.0001,TRUE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,24,24,FALSE,BZ,NA,NA
10.1080/03007995.2021.1971182,34445916,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,12,12,FALSE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,general_information,NA,NA,Medical Condition of Interest Name,pneumococcal disease,noninvasive and invasive pneumococcal disease (pd),XXXX,FALSE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,general_information,NA,NA,Countries of first author affiliations,NA,NA,switzerland,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03950622,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03480763,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,3,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03950856,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,4,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,4,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,4,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03760146,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,4,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,4,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,study_information,NA,4,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Treatment name 1,15-valent pneumococcal conjugate vaccine,"v114 (vaxneuvance, a 15-valent pneumococcal conjugate vaccine)",15-valent pneumococcal conjugate vaccine,FALSE,BZ,"Don't report the ESS for each arm, but globally for the whole reweighted IPD arms: 1710. The number reported in Table 1 are just the sum of the weights, not the ESS

Not any outcome that stands out, but outcomes reported for every STs tested, without any pooled estimate. Therefore the first one reported in the results text happens to be ST4: 0.89 <0.001 (**one sided pvalue**); 0.91 <0.001","Rsultat du serotype 1
ESS IPD (2 arms) = 1710"
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2;3,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Treatment name 2,20-valent pneumococcal conjugate vaccine,"pcv20 (prevnar 20, a 20-valent pneumococcal conjugate vaccine)",20-valent pneumococcal conjugate vaccine,FALSE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,4,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),opsonophagocytic activity (opa) geometric mean titer,30 days post-vaccination serotype-specific opa (opsonophagocytic activity) geometric mean titer,30 days post-vaccination serotype-specific opa (opsonophagocytic activity),FALSE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),Yes,No,Yes,FALSE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,1507,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,1490,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,2196,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,843,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,2,TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Sex",TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,Primary outcome: treatment effect contrast,Means Ratio,GMT ratios (Geometric mean rate ratio),Means Ratio,FALSE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,Primary outcome: unadjusted treatment effect,0.89,1.17,0.89,FALSE,BZ,serotype 4 instead of 1,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[0.74;1.07],TRUE,BZ,NA,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,Primary outcome: adjusted treatment effect,0.91,1.19,0.91,FALSE,BZ,serotype 4 instead of 1,NA
10.1080/14760584.2021.1994858,34672224,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[0.76;1.10],TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,general_information,NA,NA,Medical Condition of Interest Name,severe hemophilia a,hemophilia a,XXXX,FALSE,BZ,NA,NA
10.2147/jbm.s321288,34754257,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,general_information,NA,NA,Countries of last author affiliations,NA,NA,italy,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry, Private Data Analysis Company",TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01580293,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,"2, 3",TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,1,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01480180,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,study_information,NA,2,Number of treatment arms (clinical trial only),1,2 or more,XXXX,FALSE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Treatment name 1,damoctocog alfa pegol (bay 94-9027),damoctocog alfa pegol,damoctocog alfa pegol (bay 94-9027),FALSE,BZ,"Controls arms eligible to constitute anchors, but did not use it
Does STC as a secondary sensitivity analysis, but results not reported in this form","""The use of MAIC or STC instead of naive (nonadjusted) comparison carries some limitations as it reduces bias only if all key treatment modifiers and prognostic factors are included for an adjustment."" 
==> Les auteurs considrent qu'ils ont pris en compte des facteurs pronostiques/modificateurs d'effet ?
""It is also possible that there are other unknown effect modifiers that were not considered in the analysis""   ==> effect modifiers considered in the analysis ?"
10.2147/jbm.s321288,34754257,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Treatment name 2,turoctocog alfa pegol (n8-gp),turoctocog alfa pegol,turoctocog alfa pegol (n8-gp),FALSE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),mean annualized bleeding rate,annualized bleeding rate (abr),mean annualized bleeding rate,FALSE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,175,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,102,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,61.94,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),NA,NA,Not mentioned,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,NA,NA,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)",TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,Incidence Rate Ratio,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,1.1,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,0.4492,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,1.11,TRUE,BZ,NA,NA
10.2147/jbm.s321288,34754257,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.449,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,general_information,NA,NA,Medical Condition of Interest Name,moderate-to-severe plaque psoriasis,moderate-to-severe plaque psoriasis (patients that are inadequate responders to ustekinumab),XXXX,FALSE,BZ,NA,NA
10.2147/ptt.s326121,34765537,general_information,NA,NA,Countries of first author affiliations,NA,NA,uk,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,general_information,NA,NA,Countries of last author affiliations,NA,NA,germany,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)",NA,NA,"Academic, Pharmaceutical Industry",TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",Yes,Not mentioned,XXXX,FALSE,BZ,NA,NA
10.2147/ptt.s326121,34765537,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01708603,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,2,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT01708629,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,3,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02203032,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Treatment name 1,NA,NA,brodalumab,TRUE,BZ,NA,"""One possible limitation is that MAIC is based on the assumption that all effect modifiers and prognostic factors have been accounted for in the analysis.""
==> Est ce que a implique qu'ils considrent que les covariables prises en compte sont ""effect modifiers""/""prognosis facotors"" ?"
10.2147/ptt.s326121,34765537,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1;2,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Treatment name 2,guselkumab,guselkuma,guselkumab,FALSE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Form of the indirect comparison,NA,NA,"Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)",TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),psoriasis area and severity index 90 rate,proportions of patients who achieved pasi 90 (psoriasis area severity index) at weeks 12,proportions of patients who achieved pasi 90 (psoriasis area severity index) at weeks 12,FALSE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Nothing mentioned, not reported",TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of prognostic factors of the variables,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,135,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,121,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,90,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported","Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,11,TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,Primary outcome: treatment effect contrast,Rate difference,Proportions difference,Risk difference,FALSE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,Primary outcome: adjusted treatment effect,14.6,14.60%,14.6,FALSE,BZ,NA,NA
10.2147/ptt.s326121,34765537,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,0.002,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,general_information,NA,NA,Medical Condition of Interest Name,NA,NA,type 2 diabetes,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,general_information,NA,NA,Countries of first author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,general_information,NA,NA,Countries of last author affiliations,NA,NA,usa,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)","Academic, Pharmaceutical Industry, Private Data Analysis Company","Academic, Pharmaceutical Industry",XXXX,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",Yes,Not mentioned,XXXX,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,1,Clinical Trial,Yes,No,XXXX,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03989232,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,3,Patient-level data used,Yes,No,XXXX,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,3,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,3,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT03495102,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,3,Country where the clinical trial/observational study was conducted (international if more than one),NA,NA,international,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,3,Phase of the clinical trial (clinical trial only),NA,NA,3,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,study_information,NA,3,Number of treatment arms (clinical trial only),NA,NA,2 or more,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Treatment name 1,semaglutide 2.0 mg,semaglutide 2.0 m,semaglutide 2.0 mg,FALSE,BZ,"Multi-level meta regression 
Talk about the possibility to adjust for different populations, but how is that possible without IPD ? Should look into the methodology of ML-NMR
Not clear how to decide the sample size of the anchor arms",Sensitivity analysis 1 = Unadjusted comparison
10.1210/clinem/dgab905,34922383,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Treatment name 2,dulaglutide 3.0,dulaglutide 3.0 mg,dulaglutide 3.0 mg,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Type of population-adjusted indirect comparisons performed,Multilevel network meta-regression,Multilevel Network Meta-regression,Multilevel network meta-regression,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Form of the indirect comparison,NA,NA,Larger network (ie involving more than 2 studies),TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change in baseline hba1c,change from baseline in hba1c,change from baseline in hba1c,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,No,No,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Treatment name 1,semaglutide 2.0mg,semaglutide 2.0 mg,semaglutide 2.0 mg,FALSE,BZ,NA,Sensitivity analysis 1 = Unajusted comparison
10.1210/clinem/dgab905,34922383,methodology,2,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Treatment name 2,NA,NA,dulaglutide 4.5 mg,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Study 'number(s)' for treatment 2,NA,NA,3,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Type of population-adjusted indirect comparisons performed,Multilevel network meta-regression,Multilevel Network Meta-regression,Multilevel network meta-regression,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Anchored comparison?,NA,NA,Yes,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Form of the indirect comparison,NA,NA,Larger network (ie involving more than 2 studies),TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),change in baseline hba1c,change from baseline in body weight,change from baseline in hba1c,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Primary outcome: variable type,NA,NA,"Continuous (count, mean, ...)",TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose),TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Inclusion of prognostic factors in the adjustment/matching model,NA,NA,No,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,NA,NA,Yes,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,methodology,2,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,No,No,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,616,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,612,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,480,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,480,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,481,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,481,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,Primary outcome: treatment effect contrast,Means difference,Estimated Treatment Difference,Means difference,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,Primary outcome: unadjusted treatment effect,-0.47,-0.41,-0.47,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[-0.69;-0.23],[-0.67;-0.16],[-0.69;-0.23],FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,-0.44,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-0.68;-0.19],TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,614,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,"If anchored comparison, sample size of the population of interest in the non IPD treatment anchor arm",NA,NA,612,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,480,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",NA,NA,480,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,"If anchored comparison, initial sample size of the population of interest in the IPD anchor arm",NA,NA,481,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,"If anchored comparison, effective sample size after reweighting for MAIC; or sample size used in the regression model for STC in the IPD anchor arm",NA,NA,481,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,Number of covariates adjusted for/matched on,NA,NA,3,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,Covariates adjusted for/matched on in the indirect comparison,"Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,Primary outcome: treatment effect contrast,Means difference,Estimated Treatment Difference,Means difference,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,Primary outcome: unadjusted treatment effect,-0.31,-0.25,-0.31,FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",[-0.53;-0.08],[-0.51;0.01],[-0.53;-0.08],FALSE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,Primary outcome: adjusted treatment effect,NA,NA,-0.28,TRUE,BZ,NA,NA
10.1210/clinem/dgab905,34922383,results,2,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[-0.52;-0.03],TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,general_information,NA,NA,Medical Condition of Interest Name,relapsed or refractory aggressive large b-cell lymphomas,relapsed or refractory diffuse large b-cell lymphoma,XXXX,FALSE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,general_information,NA,NA,Countries of first author affiliations,NA,NA,france,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,general_information,NA,NA,Countries of last author affiliations,NA,NA,canada,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,general_information,NA,NA,"Positions of study investigators (for any authors of the article, any that applies)","Academic, Private Data Analysis Company, Pharmaceutical Industry","Academic, Pharmaceutical Industry, Private Data Analysis Company",XXXX,FALSE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,general_information,NA,NA,"At least one author affiliated with a department of Biostatistics, Epidemiology, Public Health, Pharmacoepidemiology, or a Clinical Research unit, or private data analysis company",NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,general_information,NA,NA,Mentioned sources of funding,NA,NA,Pharmaceutical Industry,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,general_information,NA,NA,"Ties with pharmaceutical industry mentionned in competing interest/conflict of interest/disclaimer, or any equivalent section in the article",NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,general_information,NA,NA,Mention of a systematic review to find the studies to compare treatments of interest,NA,NA,No,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,1,Patient-level data used,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,1,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,1,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02631044,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,1,Phase of the clinical trial (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,1,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,1,Country where the clinical trial/observational study was conducted (international if more than one),NA,us,XXXX,FALSE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,2,Patient-level data used,NA,NA,No,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,2,Clinical Trial,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,2,NCT (only for clinical trial registered on clinicaltrials.gov),NA,NA,NCT02445248,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,2,Phase of the clinical trial (clinical trial only),NA,NA,2,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,2,Number of treatment arms (clinical trial only),NA,NA,1,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,study_information,NA,2,Country where the clinical trial/observational study was conducted (international if more than one),NA,international,XXXX,FALSE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Treatment name 1,liso-cel,lisocabtagene maraleucel,lisocabtagene maraleucel,FALSE,BZ,"They say that ""Balance was assessed using the absolute value of the standardized mean difference"", whereas covariate balance may not be checked in that context? (see Phillippo 2016). 
Talk about the distinction prognostic factors and treatment effect modifiers, but doesn't actually give any indication for the status of any specific included factor
**Uncommon MAIC methodology: first step of direct matching, then weighting**",Renal function = comorbidity
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Study 'number(s)' for treatment 1,NA,NA,1,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Treatment name 2,NA,NA,tisagenlecleucel,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Study 'number(s)' for treatment 2,NA,NA,2,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Type of population-adjusted indirect comparisons performed,NA,NA,MAIC,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Anchored comparison?,NA,NA,No,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Form of the indirect comparison,NA,NA,Simple (ie treatments effects extracted from two studies),TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Definition of a single primary outcome for the indirect comparison,NA,NA,"No primary outcome defined, or multiple primary outcomes without any clear distinction between them",TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Primary Outcome Name (first one mentioned in the text of the results part if no primary outcome defined),objective response rate,objective response rates (orr),objective response rate,FALSE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Primary outcome: variable type,NA,NA,Binary (eg rates),TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Justification for selecting variables to be included in the adjustment model (in the main text),NA,NA,"Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)",TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Inclusion of prognostic factors in the adjustment/matching model,No discussion (in the main text) of the status of prognostic factors of the variables,Yes,Yes,FALSE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Inclusion of treatment-effect modifiers in the adjustment/matching model,No discussion (in the main text) of the status of treatment-effect modifiers of the variables,Yes,Yes,FALSE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,"Mention of the MAIC weights estimation model / STC adjustment model details in the main text **or supplemental materials** (ie matching on first moment, second moment, including interaction term, etc)",NA,NA,No,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,methodology,1,NA,Discussion of the choice of the scale for the outcome in the main text (ie natural outcome scale vs transformed outcome scale),NA,NA,No,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,Sample size of the population of interest in the non IPD treatment arm,NA,NA,111,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,Initial sample size of the population of interest in the IPD treatment arm,NA,NA,256,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,"Sample size in the IPD treatment arm used in the indirect comparison, ie effective sample size after reweighting for MAIC; or sample size used in the regression model for STC",180,164,164,FALSE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,Reporting of a weights' distribution evaluation (MAIC),"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",Not mentioned,"Yes, mentions that the weights distribution has been studied, but weights distribution not reported",FALSE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,Reporting of the list of the covariates adjusted for/matched on,NA,NA,Yes,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,Number of covariates adjusted for/matched on,NA,NA,6,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,Covariates adjusted for/matched on in the indirect comparison,"Past treatments for the disease of interest, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)","Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)",FALSE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,Primary outcome: treatment effect contrast,NA,NA,OR,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,Direction of the treatment effect contrast: IPD treatment is:,NA,NA,"Numerator if ratio, or left side if difference",TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,Primary outcome: unadjusted treatment effect,NA,NA,2.49,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,"p-value for the unadjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX-Y.YY])",NA,NA,[1.52;4.07],TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,Primary outcome: adjusted treatment effect,NA,NA,2.78,TRUE,BZ,NA,NA
10.1186/s40164-022-00268-z,35337365,results,1,NA,"p-value for the adjusted treatment effect (or 95 CI if pvalue is not provided, written as [X.XX;Y.YY])",NA,NA,[1.63;4.74],TRUE,BZ,NA,NA
